Table 1.
Baseline characteristics of COVID-19 patients who received tissue plasminogen activator
| Patient Characteristics | Total number of patients (n = 57) |
|---|---|
| Age (yr), mean ± SD | 60.8 ± 10.8 |
| Sex, n (%) | |
| Male | 41 (71.9) |
| Female | 16 (28.1) |
| Comorbidities, n (%) | |
| Asthma | 7 (12.3) |
| Chronic obstructive lung disease | 3 (5.3) |
| Interstitial lung disease | 3 (5.3) |
| Smoking history | |
| Current smoker | 4 (7.0) |
| Former smoker | 15 (26.3) |
| Never smoker | 26 (45.6) |
| Hypertension | 32 (56.1) |
| Obstructive sleep apnea | 5 (8.8) |
| Obesity | 31 (54.4) |
| Body mass index (kg/m2), mean ± SD | 31.5 ± 7.0 |
| Diabetes mellitus | 23 (40.4) |
| Hyperlipidemia | 16 (28.1) |
| Coronary artery disease | 9 (15.8) |
| Chronic kidney disease | 1 (1.8) |
| Human immunodeficiency virus infection | 1 (1.8) |
| Malignancy | 2 (3.5) |
| Multiple myeloma | 1 (1.8) |
| Chronic lymphocytic leukemia | 1 (1.8) |
| Hypothyroidism | 3 (5.3) |
| Atrial fibrillation | 1 (1.8) |
| Heart failure with reduced ejection fraction | 2 (3.5) |
| Heart failure with preserved ejection fraction | 2 (3.5) |
| Non-alcoholic fatty liver disease | 1 (1.8) |
| Rheumatoid arthritis | 2 (3.5) |
| Parkinson’s disease | 1 (1.8) |
| Hospital LOS (d), median [IQR] | 17 [11, 27.5] |
Value is shown as mean ± SD or median [Q1, Q3]
SD standard deviation; LOS length of stay